X hits on this document

160 views

0 shares

0 downloads

0 comments

41 / 57

ASCET (PFA-100) AHA SS 11/2010

Results

Composite Endpoint when ASA no RPR (n=373) 10.5% vs ASA high RPR (n=130) 13.1% p=0.44

Composite Endpoint with RPR on ASA when treated with ASA  13.1% (n=130) or Clopidrogel 7.8% (n=129) p=0.16

26% of patients had RPR while on ASA by PFA-100

Conclusions

No difference in composite endpoints

RPR by PFA-100 did NOT predict clinical outcome

Trend seems to indicate fewer endpoints using clopidrogel in patients with high RPR vs. ASA

Document info
Document views160
Page views160
Page last viewedWed Dec 07 08:50:08 UTC 2016
Pages57
Paragraphs810
Words3494

Comments